Illumina, Inc. (ILMN) Stock Score, Valuation & Financial Research
Illumina, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 36/100.
Quick answer for ILMN
Illumina, Inc. currently has a Wall Street Score of 36/100. The stored market price is $206.45. Its financial score is 36/100. Its valuation score is 10/100. The latest WSS change is +0.3 points. These figures are a research snapshot, not a buy or sell recommendation.
What Illumina, Inc. does
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, c
ILMN financial snapshot
- Wall Street Score:
- 36/100
- Current price:
- $206.45
- Market capitalization:
- $31.24B
- Revenue:
- $4.49B
- Net income:
- $825.0M
- Free cash flow:
- $931.0M
- Cash:
- $1.04B
- Total debt:
- $2.53B
- EPS:
- 5.48
- P/E ratio:
- 37.7x
- Financial score:
- 36/100
- Valuation score:
- 10/100
- Revenue score:
- 15/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $931.0M, showing positive cash generation.
- The balance sheet shows $1.04B of cash versus $2.53B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.3 points: ILMN increased 0.3 points because Revenue improved by 2 points.
What the numbers mean
Its current valuation score is 10/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 36/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research ILMN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.